Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | IDH1 | O75874 | 4/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799368 | 0.77 | HSP90AB1 (0.50) | HSP90AB1PARP1ALOX15LMNAHTT | |
| SCHEMBL17050409 | 0.76 | IDH1 (0.41) | HSP90AB1IDH1 | |
| SCHEMBL29620470 | 0.67 | ADAM17 (0.34) | IDH1 | |
| SCHEMBL29620459 | 0.67 | IDH1 (0.40) | IDH1ALOX15 | |
| SCHEMBL17050410 | 0.64 | HSP90AB1 (0.34) | HSP90AB1IDH1 | |
| SCHEMBL12545311 | 0.61 | HPGD (0.42) | HSP90AB1IDH1LMNA | |
| SCHEMBL17050405 | 0.61 | IDH1 (0.47) | HSP90AB1IDH1HTT | |
| SCHEMBL21481251 | 0.61 | IDH1 (0.41) | HSP90AB1IDH1LMNA | |
| SCHEMBL805483 | 0.61 | PARP1 (0.51) | PARP1ALOX15LMNAHTTPARP2 | |
| SCHEMBL22216371 | 0.61 | DRD2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | HSP90AB1 2956/4885PARP1 4529/4885IDH1 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.